LAG3 and neoplasm: Here, we report the findings of a preclinical study of ZGGS15, a novel bispecific monoclonal antibody (BsAb) that can simultaneously inhibit LAG-3 and TIGIT alone or in combination with an anti-PD-1 antibody, exhibiting exceptional anti-tumor efficacy.